TGF-β receptor I conditional knockout mice develop spontaneous squamous cell carcinoma

Cell Cycle

Volumn 6, Issue 11, 2007, Pages 1360-1366

  Honjo, Yasuyuki ^a   Bian, Yansong ^a   Kawakami, Koji ^c   Molinolo, Alfredo ^b   Longenecker, Glenn ^a   Boppana, Ramanamurthy ^a   Larsson, Jonas ^d   Karlsson, Stefan ^d   Gutkind, J Silvio ^b   Puri, Raj K ^c   Kulkarni, Ashok B ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cre lox P system; Cytotoxin; Head and neck cancer; IL 13; Squamous cell carcinoma; TGF ; TGF receptor I

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 13; INTERLEUKIN 13 CYTOTOXIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG; ACTIVIN RECEPTOR 1; CRE RECOMBINASE; EXOTOXIN; HYBRID PROTEIN; IL13 PE38; IL13-PE38; INTEGRASE; INTERLEUKIN 13 RECEPTOR ALPHA2; NEUROFILAMENT PROTEIN; NEUROFILAMENT PROTEIN H; SYNTHETIC DNA; TGF BETA TYPE I RECEPTOR; TGF-BETA TYPE I RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANUS CARCINOMA; ARTICLE; CARCINOGENESIS; CARCINOGENICITY; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; GENE DELETION; IC 50; IMMUNE RESPONSE; IMMUNOFLUORESCENCE TEST; IMMUNOSURVEILLANCE; KNOCKOUT MOUSE; MALE; MELANOMA CELL; MOUSE; NERVE CELL; NEUROFILAMENT; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING; ANIMAL; ANTIBODY SPECIFICITY; ANUS TUMOR; BIOSYNTHESIS; BRAIN; CANCER TRANSPLANTATION; CROSS BREEDING; DRUG EFFECT; DRUG SCREENING; FAMILIAL CANCER; GENETICS; HEAD AND NECK TUMOR; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; NUDE MOUSE; PHYSIOLOGY; PRENATAL DEVELOPMENT; TUMOR CELL LINE;

MUS; MUS MUSCULUS;

ACTIVIN RECEPTORS, TYPE I; ANIMALS; ANTINEOPLASTIC AGENTS; ANUS NEOPLASMS; BRAIN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CROSSES, GENETIC; DRUG SCREENING ASSAYS, ANTITUMOR; EXOTOXINS; FEMALE; GENES, SYNTHETIC; HEAD AND NECK NEOPLASMS; INTEGRASES; INTERLEUKIN-13; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; MALE; MICE; MICE, KNOCKOUT; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NEOPLASTIC SYNDROMES, HEREDITARY; NEUROFILAMENT PROTEINS; ORGAN SPECIFICITY; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RECOMBINANT FUSION PROTEINS;

EID: 34547678615     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.6.11.4268     Document Type: Article

References (56)

1. Wakefield LM, Roberts AB. TGF-β signaling: Positive and negative effects on tumorigenesis. Curr Opin Genet Dev 2002; 12:22-9.
2. Roberts AB, Wakefield LM. The two faces of transforming growth factor β in carcinogenesis. Proc Natl Acad Sci USA 2003; 100:8621-3.
3. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signaling. Nature 2003; 425:577-84.
4. Engle SJ, Hoying JB, Boivin GP, Ormsby I, Gartside PS, Doetschman T. Transforming growth factor β1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res 1999; 59:3379-86.
5. Schwarte-Waldhoff I, Volpert OV, Bouck NP, Sipos B, Hahn SA, Klein-Scory S, Luttges J, Kloppel G, Graeven U, Eilert-Micus C, Hintelmann A, Schmiegel W. Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc Natl Acad Sci USA 2000; 97:9624-9.
6. Piek E, Roberts AB. Suppressor and oncogenic roles of transforming growth factor-beta and its signaling pathways in tumorigenesis. Adv Cancer Res 2001; 83:1-54.
7. Kulkarni, Thyagarajan T, Letterio JJ. Function of cytokines within the TGF-beta superfamily as determined from transgenic and gene knockout studies in mice. Curr Mol Med 2002; 2:303-27.
8. Bierie B, Moses HL. Tumour microenvironment: TGFbeta: The molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006; 6:506-20.
9. Glick AB, Lee MM, Darwiche N, Kulkarni AB, Karlsson S, Yuspa SH. Targetd deletion of the TGF-β1 gene causes rapid progression to squamous cell carcinoma. Gene Dev 1994; 8:2429-40.
10. Larsson J, Blank U, Helgadottir H, Bjornsson JM, Ehinger M, Goumans MJ, Fan X, Leveen P, Karlsson S. TGF-β signaling-deficient hematopoietic stem cells have normal self-renewal and regenerative ability in vivo despite increased proliferative capacity in vitro. Blood 2003; 102:3129-35.
11. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, Washington MK, Neilson EG, Moses HL. TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004; 303:848-51.
12. Gorelik L, Flavell RA. Transforming growth factor-beta in T-cell biology. Nat Rev Immunol 2002; 2:46-53.
13. Gu H, Zou YR, Rajewsky K. Independent control of immunoglobulin switch recombination at individual switch regions evidenced through Cre-loxP-mediated gene targeting. Cell 1993; 73:1155-64.
14. Zou YR, Muller W, Gu H, Rajewsky K. Cre-loxP-mediated gene replacement: A mouse strain producing humanized antibodies. Curr Biol 1994; 4:1099-103.
15. Hirasawa M, Cho A, Sreenath T, Sauer B, Julien JP, Kulkarni AB. Neuron-specific expression of Cre recombinase during the late phase of brain development. Neurosci Res 2001; 40:125-32.
16. De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol 2003; 200:429-47.
17. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: The roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 2006; 90:1-50.
18. Kim BG, Li C, Qiao W, Mamura M, Kasperczak B, Anver M, Wolfraim L, Hong S, Mushinski E, Potter M, Kim SJ, Fu XY, Deng C, Letterio JJ. Smad4 signaling in T cells is required for suppression of gastrointestinal cancer. Nature 2006; 441:1015-19.
19. Tu WH, Thomas TZ, Masumori N, Bhowmick NA, Gorska AE, Shyr Y, Kasper S, Case T, Roberts RL, Shappell SB, Moses HL, Matusik RJ. The loss of TGF-β signaling promotes prostate cancer metastasis. Neoplasia 2003; 5:267-77.
20. Glick AB, Kulkarni AB, Tennenbaum T, Hennings H, Flanders KC, O'Reilly M, Sporn MB, Karlsson S, Yuspa SH. Loss of expression of transforming growth factor β in skin and skin tumors is associated with hyperproliferation and a high risk for malignant conversion. Proc Natl Acad Sci USA 1993; 90:6076-80.
21. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM, Karlsson S. Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993; 90:770-4.
22. Kawakami K, Puri RK. Interleukin-13 and cancer. In: Brombacher F, ed. Interleulin-13. Texas: Landes Bioscience Publishing, 2003:65-78.
23. Kawakami M, Kawakami K, Kasperbauer JL, Hinkley LL, Tsukuda M, Strome SE, Puri RK. Interleukin-13 receptor a2 chain in human head and neck cancer serves as a unique diagnostic marker. Clin Cancer Res 2003; 9:6381-8.
24. Caput D, Laurent P, Kaghad M, Lelias JM, Lefort S, Vita N, Ferrara P. Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor a chain. J Biol Chem 1996; 271:16921-6.
25. Joshi BH, Kawakami K, Leland P, Puri RK. Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: Differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin. Clin Cancer Res 2002; 8:1948-56.
26. Debinski W, Obiri NI, Pastan I, Puri RK. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J Biol Chem 1995; 270:16775-80.
27. Kioi M, Kawakami K, Puri RK. Analysis of antitumor activity of an IL-13 receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin. Clin Cancer Res 2004; 10:6231-8.
28. Kawakami M, Kawakami K, Puri RK. Apoptotic pathways of cell death induced by an interleukin-13 receptor targeted recombinant cytotoxin in head and neck cancer cells. Cancer Immunol Immunother 2002; 50:691-700.
29. Kawakami K, Kawakami M, Joshi BH, Puri RK. Interleukin-13 receptor targeted cancer therapy in an immunodeficient animal model of human head and neck cancer. Cancer Res 2001; 61:6194-200.
30. Kawakami M, Kawakami K, Puri RK. Tumor regression mechanisms by interleukin-13 receptor-targeted cancer therapy involve apoptotic pathways. Int J Cancer 2003; 103:45-52.
31. Ohshima T, Ward JM, Huh CG, Longenecker G, Veeranna, Pant HC, Brady RO, Martin LJ, Kulkarni AB. Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc Natl Acad Sci USA 1996; 93:11173-8.
32. Jakubzick C, Kunkel SL, Joshi BH, Puri RK, Hogaboam CM. Interleukin-13 fusion cytotoxin arrests Schistosoma mansoni egg-induced pulmonary granuloma formation in mice. Am J Pathol 2002; 161:1283-97.
33. Baisse B, Bian YS, Benhattar J. Microdissection by exclusion and DNA extraction for multiple PCR analyses from archival tissue sections. Biotechniques 2000; 28:856-62.
34. Kawakami K, Husain SR, Bright RK, Puri RK. Gene transfer of interleukin 13 receptor α2 chain dramatically enhances the antitumor effect of IL-13 receptor-targeted cytotoxin in human prostate cancer xenografts. Cancer Gene Ther 2001; 8:861-8.
35. Chalmers KA, Love S. Neurofibrillary tangles may interfere with Smad 2/3 signaling in neurons. J Neuropathol Exp Neurol 2007; 66:158-67.
36. Donaldson DD, Whitters MJ, Fitz LJ, Neben TY, Finnerty H, Henderson SL, O'Hara Jr RM, Beier DR, Turner KJ, Wood CR, Collins M. The murine IL-13 receptor α2: Molecular cloning, characterization, and comparison with murine IL-13 receptor α1. J Immunol 1998; 161:2317-24.
37. Kreitman RJ, Puri RK, Pastan I. A circularly permuted recombinant interleukin 4 toxin with increased activity. Proc Natl Acad Sci USA 1994; 91:6889-93.
38. Puri RK, Hoon DS, Leland P, Snoy P, Rand RW, Pastan I, Kreitman RJ. Preclinical development of a recombinant toxin containing circularly permuted interleukin-4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma. Cancer Res 1996; 56:5631-7.
39. Kawakami K, Kawakami M, Puri RK. Overexpressed cell surface interleukin-4 receptor molecules can be successfully targeted for antitumor cytotoxin therapy. Crit Rev Immunol 2001; 21:299-310.
40. Krieglstein K, Strelau J, Schober A, Sullivan A, Unsicker K. TGF-beta and the regulation of neuron survival and death. J Physiol Paris 2000; 296:25-30.
41. Lippa CF, Smith TW, Flanders KC. Transforming growth factor-beta: Neuronal and glial expression in CNS degenerative diseases. Neurodegeneration 1995; 4:425-32.
42. Flanders KC, Ren RF, Lippa CF. Transforming growth factor-betas in neurodegenerative disease. Prog Neurobiol 1998; 54:71-85.
43. Flanders KC, Lippa CF, Smith TW, Pollen DA, Sporn MB. Altered expression of transforming growth factor-beta in Alzheimer's disease. Neurology 1995; 45:1561-9.
44. Lu SL, Herrington H, Reh D, Weber S, Bornstein S, Wang D, Li AG, Tang CF, Siddiqui Y, Nord J, Andersen P, Corless CL, Wang XJ. Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev 2006; 20:1331-42.
45. Munoz NM, Upton M, Rojas A, Washington MK, Lin L, Chytil A, Sozmen EG, Madison BB, Pozzi A, Moon RT, Moses HL, Grady WM. Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation. Cancer Res 2006; 66:9837-44.
46. Quan T, He T, Kang S, Voorhees JJ, Fisher GJ. Ultraviolet irradiation alters transforming growth factor beta/smad pathway in human skin in vivo. J Invest Dermatol 2002; 119:499-506.
47. He W, Cao T, Smith DA, Myers TE, Wang XJ. Smads mediate signaling of the TGF-β superfamily in normal keratinocytes but are lost during skin chemical carcinogenesis. Oncogene 2001; 20:471-83.
48. Peters EM, Botchkarev VA, Botchkareva NV, Tobin DJ, Paus R. Hair-cycle-associated remodeling of the peptidergic innervation of murine skin, and hair growth modulation by neuropeptides. J Invest Dermatol 2001; 116:236-45.
49. Akiyama M, Dale BA, Sun TT, Holbrook KA. Characterization of hair follicle bulge in human fetal skin: The human fetal bulge is a pool of undifferentiated keratinocytes. J Invest Dermatol 1995; 105:844-50.
50. Guinard D, Usson Y, Guillermet C, Saxod R. Merkel complexes of human digital skin: Three-dimensional imaging with confocal laser microscopy and double immunofluorescence. J Comp Neurol 1998; 398:98-104.
51. Tanaka T, Narisawa Y. Three-dimensional comparative study of Merkel cell distribution in various body sites of guinea pigs and rats. Arch Dermatol Res 2000; 292:173-9.
52. Tachibana T. The Merkel cell: Recent findings and unresolved problems. Arch Histol Cytol 1995; 58:379-96.
53. Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, Donaldson DD, Carbone DP, Paul WE, Berzofsky JA. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 2000; 6:515-20.
54. Ostrand-Rosenberg S, Clements VK, Terabe M, Park JM, Berzofsky JA, Dissanayake SK. Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent. J Immunol 2002; 169:5796-804.
55. Terabe M, Matsui S, Park JM, Mamura M, Noben-Trauth N, Donaldson DD, Chen W, Wahl SM, Ledbetter S, Pratt B, Letterio JJ, Paul WE, Berzofsky JA. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: Abrogation prevents tumor recurrence. J Exp Med 2003; 198:1741-52.
56. Park JM, Terabe M, van den Broeke LT, Donaldson DD, Berzofsky JA. Unmasking immunosurveillance against a syngeneic colon cancer by elimination of CD4+ NKT regulatory cells and IL-13. Int J Cancer 2005; 114:80-7.